Cardiovascular API Products
探索 心血管的 Products
苯磺酸氨氯地平
心血管的
阿哌沙班
心血管的
贝派地酸
心血管的
硫酸氢氯吡格雷（晶型1）
心血管的
硫酸氢氯吡格雷（晶型2）
心血管的
甲磺酸达比加群酯
心血管的
甲磺酸多沙唑嗪
心血管的
依折麦布
心血管的
磺达肝葵钠
心血管的
拉西地平
心血管的
氯沙坦钾
心血管的
马瓦卡坦
心血管的
琥珀酸美托洛尔
心血管的
雷米普利
心血管的
利伐沙班
心血管的
沙库巴曲缬沙坦钠
心血管的
Tafamidis Free Acid
心血管的
氯苯唑酸葡甲胺
心血管的
替格瑞洛
心血管的
曲前列尼尔
心血管的
曲前列尼尔二乙醇胺
心血管的
缬沙坦
心血管的
阿托伐他汀钙（无定型 晶型1）
心血管的
USPs of Cardiovascular API
- Well-controlled impurity profile (APIs meets current and future stringent impurity limits).
- Improved API flow property through controlled crystallization and process modifications to ease formulation development.
- Completely backward integrated on the KSMs to ensure uninterrupted supplies.
- Robust and sustainable supply chain.
- Eligible to file DMF’s globally in all the markets.
- Comprehensive assessment of synthetic routes and all toxicological attributes.
- All GTIs are controlled below TTC limits.
- Robust advanced analytical techniques to detect potential nitrosamine impurities.
- Process development through QBD approach.
- Customized particle sizes (PSD) to meet formulation requirements.
- Successful BE/dossier filing record of accomplishment in the markets.
- Multiple synthetic steps manufactured in-house.
- API and KSM process with no IP Issues.
- Comprehensive assessment of synthetic routes and all toxicological attributes.
Get access to Dr. Reddys largest Cardiovascular API portfolios to support your formulation success.
Dr. Reddy's offers a wide selection of cardiovascular active pharmaceutical ingredients used in the production of formulations to treat cardiovascular diseases. Our portfolio includes a broad class of cardiovascular molecules: HMG–CoA reductase inhibitors (statins), adenosine triphosphate-citrate lyase (ACL) inhibitors, calcium channel blockers, angiotensin II receptor antagonists, anticoagulants, beta-blockers, lipid modifiers, and others.
Dr. Reddy's is well-positioned to meet the global demands of Cardiovascular APIs. As a Cardiovascular API manufacturer and supplier, we follow a multistage synthesis to ensure supply chain sustainability and compliance with global regulatory requirements. In addition, Dr. Reddy's has established solid strategic sourcing, logistics partnerships and works closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.
Look at Dr. Reddy's broad selection of active pharmaceutical ingredients cardiovascular drugs used to treat cardiovascular diseases like hypertension, angina, benign prostate hyperplasia, pulmonary arterial hypertension, heredity angioedema, and many more.
探索 other Therapeutic categories.
Category-Cardiovascular Faq
Our portfolio includes a broad class of cardiovascular molecules:
- HMG–CoA reductase inhibitors (statins)
- Adenosine triphosphate-citrate lyase (ACL) inhibitors
- Calcium channel blockers
- Angiotensin II receptor antagonists
- Anticoagulants
- Beta-blockers
- Others
The global cardiovascular drugs market size is projected to hit around USD 231.7 billion by 2030 from valued at USD 155.6 billion in 2021 and growing at a CAGR of 4.52% from 2022 and 2030.
HMG–CoA inhibitors - decrease cholesterol levels. ACL Inhibitors - Direct inhibition of ACL by ETC-1002 lowers cytosolic acetyl CoA. Calcium channel blockers - prevent calcium from entering the cells of the heart & arteries. Angiotensin ii receptor antagonists - help relax veins & arteries to lower BP & make it easier for your heart to pump blood.
A control strategy has been defined using the QbD approach at every synthesis step and ensures that Dr. Reddy's APIs are free from potential genotoxic and carcinogenic impurities
Dr. Reddy's is well-positioned to meet the global demands of Cardiovascular APIs. We follow a multistage synthesis to ensure supply chain sustainability and compliance with global regulatory requirements. We established solid strategic sourcing and logistics partnerships and work closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.
Used to treat or improve symptoms of cardiovascular conditions including high blood pressure and heart failure.
免责声明
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。